Основная статистика
| LEI | 549300KS9771JZ234890 |
| CIK | 1595248 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Genprex, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 19, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 18, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 15, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 15, 2025 |
Exhibit 10.1 GENPREX, INC. 2018 EQUITY INCENTIVE PLAN As Amended and Restated Effective June 30, 2025 (the “Restatement Date”) 1. Purposes of the Plan. The purposes of this Plan are to attract and retain personnel for positions with the Company, to provide additional incentive to Employees, Directors, and Consultants (collectively, “Service Providers”), and to promote the success of the Company’s |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38244 GENPREX, I |
|
| August 5, 2025 |
August 5, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| August 4, 2025 |
Exhibit 99.1 Genprex Issues Stockholder Letter and Provides 2025 Corporate Update Company Achieves Multiple Clinical Development Milestones in 2025 Patient Treatment Continues in Two Lung Cancer Clinical Trials AUSTIN, Texas — (Aug. 4, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 4, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commis |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 24, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 23, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 17, 2025 |
GENPREX, INC. 15,000,000 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-287962 GENPREX, INC. 15,000,000 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to 15,000,000 shares of our common stock, par value $0.001 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as “Lincoln Park” or the “selling stockholder.” The shares of common stoc |
|
| June 16, 2025 |
June 16, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N. |
|
| June 11, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Genprex, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Securities to Be Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount to Be Registered (1) Proposed Maximum Offering Price Per Share (2) Proposed Maximum Aggregate Offering Price (2) Fee Rat |
|
| June 11, 2025 |
Exhibit 10.1 PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of June 11, 2025, by and between GENPREX, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 11, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 11, 2025 |
As filed with the Securities and Exchange Commission on June 11, 2025. As filed with the Securities and Exchange Commission on June 11, 2025. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 2834 90-0772347 (State or other jurisdiction of incorporation or organization) (Pr |
|
| June 11, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 11, 2025, by and between GENPREX, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respec |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 6, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 14, 2025 |
Form of Placement Agency Agreement. Exhibit 10.34 WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 [*], 2025 Genprex, Inc. 3300 Bee Cave Road, #650-227 Austin, TX 78746 Attention: Ryan M. Confer Dear Mr. Confer: Subject to the terms and conditions of this letter agreement (the “Agreement”), between WestPark Capital, Inc., as lead placement agent (“Placement Agent”), and Genprex, Inc., a company organize |
|
| May 14, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.33 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [ ] [ ], 2025, between Genprex, Inc., a corporation formed under the laws of the State of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purc |
|
| May 14, 2025 |
Exhibit 4.21 PRE-FUNDED COMMON STOCK PURCHASE WARRANT GENPREX, INC. Warrant Shares: Initial Exercise Date: May , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof ( |
|
| May 14, 2025 |
Exhibit 4.20 COMMON STOCK PURCHASE WARRANT GENPREX, INC. Warrant Shares: Initial Exercise Date: May , 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise |
|
| May 14, 2025 |
Form of Placement Agent Warrant. Exhibit 4.22 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT GENPREX, INC. Warrant Shares: Initial Exercise Date: May , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the dat |
|
| May 14, 2025 |
As filed with the Securities and Exchange Commission on May 14, 2025. As filed with the Securities and Exchange Commission on May 14, 2025. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 2834 90-0772347 (State or other jurisdiction of incorporation or organization) (Pri |
|
| May 14, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Genprex, Inc. (Exact Name of Each Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee E |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38244 GENPREX, |
|
| May 7, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 7, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commissio |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 6, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commissio |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 28, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commis |
|
| April 24, 2025 |
As confidentially submitted to the Securities and Exchange Commission on April 24, 2025. |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38244 Genprex, Inc. ( |
|
| April 1, 2025 |
Exhibit 21.1 Subsidiaries of Genprex, Inc. NAME JURISDICTION OF ORGANIZATION Convergen Biotech, Inc. Delaware |
|
| April 1, 2025 |
Genprex, Inc. Insider Trading Policy. Exhibit 19.1 GENPREX, INC. INSIDER TRADING POLICY This Insider Trading Policy describes the standards of Genprex, Inc. and its subsidiaries (the "Company") on trading, and causing the trading of, the Company's securities or securities of certain other publicly traded companies while in possession of confidential information. This Policy applies to all directors, officers and employees (and their r |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-38244 CUSIP NUMBER NOTIFICATION OF LATE FILING 372446203 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transiti |
|
| April 1, 2025 |
Exhibit 3.5 AMENDMENT NO. 2 TO THE AMENDED AND RESTATED BYLAWS OF GENPREX, INC. Adopted and Approved by the Board of Directors on March 29, 2025 1. Section 8. Quorum. A. The fourth sentence of Article III, Section 8 of the Genprex, Inc. (the “Company”) Amended and Restated Bylaws, as amended (the “Bylaws”), is hereby amended and restated in its entirety to read as follows: “Except as otherwise pro |
|
| April 1, 2025 |
Exhibit 4.20 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the end of the period covered by, and as of the date of filing this Annual Report on Form 10-K of which this Exhibit 4.20 is a part, Genprex, Inc. (the “Company”) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amend |
|
| February 18, 2025 |
EXHIBIT 10.1 CERTAIN IDENTIFIED INFORMATION MARKED WITH “[***]” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (“Agreement”) is made and entered into as of as of the date of the last signature to this Agreement (“Effective Date”), by and between t |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 17, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| February 18, 2025 |
Exhibit 99.1 Genprex Provides Update on Diabetes Gene Therapy Program Signs an Amended & Restated License Agreement for Multiple Technologies for Gene Therapy for Type 1 and Type 2 Diabetes Forms a Wholly-Owned Subsidiary, Convergen Biotech, Inc., to Focus Diabetes Program Development AUSTIN, Texas — (February 18, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 7, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Comm |
|
| January 24, 2025 |
As filed with the Securities and Exchange Commission on January 24, 2025 As filed with the Securities and Exchange Commission on January 24, 2025 Registration No. |
|
| January 24, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Genprex, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common sto |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 23, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Comm |
|
| January 13, 2025 |
Exhibit 99.1 |
|
| January 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 13, 2025 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Comm |
|
| December 20, 2024 |
Genprex, Inc. Up to $7,457,412 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-271386 PROSPECTUS SUPPLEMENT (To Prospectus Supplements dated November 8, 2024, August 16, 2024, May 20, 2024 and December 13, 2023 and Base Prospectus dated June 9, 2023) Genprex, Inc. Up to $7,457,412 Common Stock This prospectus supplement (this “Fourth Sticker Supplement”) further amends, modifies, supersedes and supplements certain informa |
|
| December 16, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 16, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 20, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 19, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38244 GENPR |
|
| November 8, 2024 |
Genprex, Inc. Up to $7,536,207 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-271386 PROSPECTUS SUPPLEMENT (To Prospectus Supplements dated August 16, 2024, May 20, 2024 and December 13, 2023 and Base Prospectus dated June 9, 2023) Genprex, Inc. Up to $7,536,207 Common Stock This prospectus supplement (this “Third Sticker Supplement”) further amends, modifies, supersedes and supplements certain information contained in, |
|
| November 5, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 4, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Comm |
|
| October 24, 2024 |
GNPX / Genprex, Inc. / Otsuka Masaya - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genprex Inc. (Name of Issuer) Common Stock, par value $0.001 PER SHARE (Title of Class of Securities) 372446203 (CUSIP Number) October 22,2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuan |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 24, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Comm |
|
| October 22, 2024 |
GNPX / Genprex, Inc. / Otsuka Masaya Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Genprex Inc. (Name of Issuer) Common Stock, par value $0.001 PER SHARE (Title of Class of Securities) 372446203 (CUSIP Number) October 21,2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuan |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 15, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Comm |
|
| October 3, 2024 |
GNPX / Genprex, Inc. / Forsakringsaktiebolaget Avanza Pension - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2. Under the Securities Exchange Act of 1934 Genprex Inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 372446203 (CUSIP Number) Sept |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 26, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Co |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 4, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| August 16, 2024 |
Genprex, Inc. Up to $2,328,685 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-271386 PROSPECTUS SUPPLEMENT (To Prospectus Supplements dated May 20, 2024 and December 13, 2023 and Base Prospectus dated June 9, 2023) Genprex, Inc. Up to $2,328,685 Common Stock This prospectus supplement (this “Second Sticker Supplement”) further amends, modifies, supersedes and supplements certain information contained in, and should be re |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 13, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38244 GENPREX, I |
|
| June 27, 2024 |
Exhibit 99.1 Genprex Issues Stockholder Letter and Provides 2024 Corporate Update Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas — (June 27, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patien |
|
| June 27, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 27, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 18, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 24, 2024 |
Exhibit 10.1 FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This First Amendment (the “Amendment”) to the Executive Employment Agreement is dated as of June 24, 2024 and effective as of May 8, 2024 (the “Amendment Effective Date”) and is entered into by and between Genprex, Inc., a Delaware corporation (the “Company”) and Ryan M. Confer (the “Employee”). All capitalized terms used herein but no |
|
| June 24, 2024 |
Exhibit 10.2 SEPARATION AGREEMENT AND RELEASE THIS SEPARATION AGREEMENT AND RELEASE (including all schedules and exhibits, collectively, this “Agreement”) is made and entered into as of June 21, 2024 (the “Execution Date”), by and among, Genprex, Inc., a Delaware corporation (and together with its wholly-owned and majority-owned subsidiaries, “Genprex” or the “Company”) and Catherine Vaczy (“Vaczy |
|
| June 24, 2024 |
Exhibit 10.3 GENPREX, INC. AMENDED AND RESTATED OUTSIDE DIRECTOR COMPENSATION POLICY Genprex, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the “Outside Director |
|
| May 20, 2024 |
Genprex, Inc. Up to $2,172,381 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-271386 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated December 13, 2023 and Base Prospectus dated June 9, 2023) Genprex, Inc. Up to $2,172,381 Common Stock This prospectus supplement (this “Supplement”) amends, modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, our prospectus su |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38244 GENPREX, |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 8, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commissio |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 17, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Genprex, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common sto |
|
| April 17, 2024 |
As filed with the Securities and Exchange Commission on April 17, 2024 As filed with the Securities and Exchange Commission on April 17, 2024 Registration No. |
|
| April 1, 2024 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENPREX, INC. Rodney Varner, hereby certifies that: ONE: He is the duly elected and acting Chief Executive Officer of Genprex, Inc., a Delaware corporation. TWO: The date of filing of said corporation’s original certificate of incorporation with the Delaware Secretary of State was April 1, 2009. THREE: The Third Amended and Restated |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38244 Genprex, Inc. ( |
|
| April 1, 2024 |
Exhibit 4.20 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the end of the period covered by, and as of the date of filing this Annual Report on Form 10-K of which this Exhibit 4.20 is a part, Genprex, Inc. (the “Company”) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amend |
|
| April 1, 2024 |
Exhibit 10.3 GENPREX, INC. 2018 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. 2 2. Shares Subject to the Plan. 2 3. Administration of the Plan. 3 4. Stock Options. 6 5. Restricted Stock. 9 6. Restricted Stock Units. 9 7. Stock Appreciation Rights. 10 8. Performance Stock Units and Performance Shares. 11 9. Performance Awards. 11 10. Outside Director Limitations. 12 11. Leaves of Absence/Transfer |
|
| April 1, 2024 |
Exhibit 10.24 CERTAIN IDENTIFIED INFORMATION MARKED WITH “[***]” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This SECOND AMENDMENT (the “Second Amendment”) TO EXCLUSIVE LICENSE AGREEMENT (the “Original License Agreement”) is made effective (the “Second Amen |
|
| April 1, 2024 |
Exhibit 10.4 GENPREX, INC. EMPLOYEE STOCK OPTION GRANT NOTICE AND OPTION AGREEMENT As a key leader in our business, you are in a position to have significant influence on the performance and success of Genprex, Inc. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, you have been granted an option to purchase shares of the Company’s Com |
|
| April 1, 2024 |
Genprex, Inc. Compensation Recovery Policy. Exhibit 97.1 GENPREX, INC. COMPENSATION RECOVERY POLICY (Adopted and approved as of November 27, 2023) 1. Purpose Genprex, Inc. (the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, the Company has adopted this Compensation Recovery Policy (this “Policy”). This Policy i |
|
| March 20, 2024 |
Exhibit 4.2 COMMON STOCK PURCHASE WARRANT GENPREX, INC. Warrant Shares: Initial Exercise Date: March , 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise |
|
| March 20, 2024 |
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules AUSTIN, Texas — (March 19, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into definitive agreements for the s |
|
| March 20, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-271386 PROSPECTUS SUPPLEMENT (To Prospectus dated June 9, 2023) GENPREX, INC. 165,000 Shares of Common Stock Warrants to Purchase up to 1,542,112 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,377,112 Shares of Common Stock Placement Agent Warrants to Purchase up to 92,527 Shares of Common Stock (and the 3,011,751 Shares of Comm |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 19, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commis |
|
| March 20, 2024 |
Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT GENPREX, INC. Warrant Shares: Initial Exercise Date: March 21, 2024 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| March 20, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 19, 2024, between Genprex, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| March 20, 2024 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT GENPREX, INC. Warrant Shares: Initial Exercise Date: March , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| March 20, 2024 |
Exhibit 4.4 March 19, 2024 Holder of Warrants to Purchase Common Stock set forth on Exhibit A attached hereto Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the registered direct offering on or about the date hereof (the “Offering”) by Genprex, Inc. (the “Company”) of its common stock, par value $0.001 per share (“Common Stock”), and/or other securities of the Company |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 6, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| February 26, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 20, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| February 14, 2024 |
GNPX / Genprex, Inc. / CVI Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm244732d15sc13ga.htm SC 13G/A CUSIP No: 372446104 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Genprex, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of S |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 4, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Comm |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 30, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Comm |
|
| January 31, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENPREX, INC. Genprex, Inc. (the “Company”), a corporation duly organized and validly existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”); DOES HEREBY CERTIFY AS FOLLOWS: FIRST: That the Amended and Restated Certificate of Incorporation of the Company (as h |
|
| January 31, 2024 |
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024 Exhibit 99.1 Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024 AUSTIN, Texas — (Jan. 31, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that on February 2, 2024, the Company will implement a 1-for-40 reverse split of |
|
| January 31, 2024 |
UNITED STATES -12-31 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 31, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 5, 2024 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| January 5, 2024 |
Exhibit 99.1 |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 14, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 12, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| December 13, 2023 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT December 13, 2023 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Genprex, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this Agreement a |
|
| December 13, 2023 |
Genprex, Inc. Up to $25,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-271386 PROSPECTUS SUPPLEMENT (To Prospectus dated June 9, 2023) Genprex, Inc. Up to $25,000,000 Common Stock We have entered into an At The Market Offering Agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated December 13, 2023, relating to the sale of shares of our common stock, par value $0.001 per share, ha |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38244 GENPR |
|
| November 14, 2023 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF GENPREX, INC. (a Delaware corporation) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by t |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| October 23, 2023 |
UNITED STATES -12-31 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 18, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization |
|
| October 23, 2023 |
Exhibit 3.1 AMENDMENT NO. 1 TO THE AMENDED AND RESTATED BYLAWS OF GENPREX, INC. Adopted and Approved by the Board of Directors on October 18, 2023 1. Quorum. The first sentence of Article III, Section 8 of the Genprex, Inc. (the “Company”) Amended and Restated Bylaws (the “Bylaws”) is hereby amended and restated in its entirety to read as follows: “Except as otherwise required by law, the corporat |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| September 25, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 22, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Co |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 8, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| September 8, 2023 |
Exhibit 99.1 |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 30, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 10, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 21, 2023 |
Exhibit 16.1 August 21, 2023 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Genprex, Inc., which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K/A of the Company dated August 21, 2023, and agree with such statements contained therein as they pertain to |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38244 GENPREX, I |
|
| August 15, 2023 |
SEC FILE NUMBER 001-38244 CUSIP NUMBER 372446104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 24, 2023 |
GNPX / Genprex Inc / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 372446104 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Genprex, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 372446104 (CUSIP Number) July 18 |
|
| July 20, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-271386 PROSPECTUS SUPPLEMENT (To Prospectus dated June 9, 2023) GENPREX, INC. 7,425,744 Shares of Common Stock Warrants to Purchase up to 7,425,744 Shares of Common Stock Placement Agent Warrants to Purchase up to 445,545 Shares of Common Stock (and the 7,871,289 Shares of Common Stock Underlying the Warrants and Placement Agent Warrants) We ar |
|
| July 19, 2023 |
Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules AUSTIN, Texas, July 19, 2023 /PRNewswire/ - Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into definitive agreements |
|
| July 19, 2023 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT GENPREX, INC. Warrant Shares: Initial Exercise Date: July 21, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercis |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 18, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| July 19, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 18, 2023, between Genprex, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| July 19, 2023 |
Exhibit 4.2 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT GENPREX, INC. Warrant Shares: Initial Exercise Date: July 21, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d |
|
| July 18, 2023 |
EXHIBIT 10.1 CERTAIN IDENTIFIED INFORMATION MARKED WITH “[***]” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (“Agreement”) is made and entered into as of as of the date of the last signature to this Agreement (“Effective Date”), by and between t |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 14, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| July 18, 2023 |
Exhibit 99.1 Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh Latest license creates a comprehensive panel of gene therapies exclusively licensed by Genprex for the Company’s diabetes gene therapy program Innovative program supported by preclinical data shows statistically significant decreases in insulin requirements, increases in c-peptide level |
|
| July 14, 2023 |
Exhibit 16.1 July 14, 2023 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Genprex, Inc., which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of the Company dated July 14, 2023, and agree with such statements contained therein as they pertain to our f |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 10, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 27, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 27, 2023 |
Amended and Restated Outside Director Compensation Policy Exhibit 10.1 GENPREX, INC. AMENDED AND RESTATED OUTSIDE DIRECTOR COMPENSATION POLICY Genprex, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the “Outside Director |
|
| June 7, 2023 |
3300 Bee Cave Road, #650-227 Austin, TX 78746 3300 Bee Cave Road, #650-227 Austin, TX 78746 June 7, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| May 26, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 25, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38244 GENPREX, |
|
| May 16, 2023 |
SEC FILE NUMBER 001-38244 CUSIP NUMBER 372446104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 12, 2023 |
Exhibit 16.1 May 12, 2023 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Genprex, Inc., which were filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K/A of the Company dated April 27, 2023, and agree with such statements contained therein as they pertain to our firm. We have no |
|
| May 12, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 3, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| April 27, 2023 |
Exhibit 16.1 April 26, 2023 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Genprex, Inc. Changes in Registrant’s Certifying Accountant We have read the statements made by Genprex, Inc., which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K/A of the Company dated April 27, 2023, and agree with such stateme |
|
| April 27, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 3, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 21, 2023 |
Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) Genprex, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (3) Fee Rate Amount of Registrat |
|
| April 21, 2023 |
Form of Subordinated Note (included in Exhibit 4.6).* Exhibit 4.6 GENPREX, INC., as Issuer and ●, as Trustee INDENTURE Dated as of ● Subordinated Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between GENPREX, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicable 310(b) 5.09(a), (b) and (d) 310(c) Inapp |
|
| April 21, 2023 |
As filed with the Securities and Exchange Commission on April 21, 2023 Registration No. |
|
| April 21, 2023 |
Form of Senior Note (included in Exhibit 4.5).* Exhibit 4.5 GENPREX, INC., as Issuer and ●, as Trustee INDENTURE Dated as of ● Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between GENPREX, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicable 310(b) 5.09(a), (b) and (d) 310(c) Inapplicabl |
|
| March 31, 2023 |
Description of Registrant's Securities. Exhibit 4.18 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, Genprex, Inc. (the “Company”) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), its common stock, par value $0.001 per share (the “Common Stock”). Description of Common |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38244 Genprex, Inc. ( |
|
| March 13, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 13, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commis |
|
| March 6, 2023 |
Exhibit 16.1 March 6, 2023 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Genprex, Inc. Changes in Registrant’s Certifying Accountant We have read the statements made by Genprex, Inc., which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of the Company dated March 6, 2023, and agree with such statements |
|
| March 6, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 3, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| February 28, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-239134 PROSPECTUS SUPPLEMENT (To Prospectus dated July 17, 2020) GENPREX, INC. 3,809,524 Shares of Common Stock Warrants to Purchase up to 3,809,524 Shares of Common Stock (3,809,524 Shares of Common Stock Underlying the Warrants) We are offering (i) 3,809,524 shares of our common stock, par value $0.001 per share, and (ii) warrants to purchase |
|
| February 27, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 26, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| February 27, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 26, 2023, between Genprex, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fo |
|
| February 27, 2023 |
Exhibit 99.1 GENPREX, INC. ANNOUNCES $4 MILLION REGISTERED DIRECT OFFERING WITH A SINGLE, HEALTHCARE-FOCUSED INSTITUTIONAL INVESTOR AUSTIN, Texas, Feb. 27, 2023 /PRNewswire/ - Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into a secu |
|
| February 27, 2023 |
EX-4.1 2 ex480883.htm EXHIBIT 4.1 Exhibit 4.1 WARRANT TO PURCHASE SHARES OF COMMON STOCK GENPREX, INC. Warrant Shares: 3,809,524 Issue Date: March 1, 2023 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 18, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| February 17, 2023 |
As filed with the Securities and Exchange Commission on February 17, 2023 As filed with the Securities and Exchange Commission on February 17, 2023 Registration No. |
|
| February 17, 2023 |
EX-FILING FEES 4 ex475944.htm EXHIBIT FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Genprex, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Aggregate Offering Price(2 |
|
| January 6, 2023 |
Exhibit 99.1 |
|
| January 6, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 6, 2023 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 29, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| January 5, 2023 |
EXHIBIT 99.2 Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh Technologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of this Disease for the Millions of Patients Around the World with Type 1 or Type 2 Diabetes AUSTIN, Texas ? (January 5, 2023) ? Genprex, Inc. (?Genprex? or |
|
| January 5, 2023 |
EX-10.1 2 ex460640.htm EXHIBIT 10.1 EXHIBIT 10.1 CERTAIN IDENTIFIED INFORMATION MARKED WITH “[***]” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (“Agreement”) is made and entered into as of as of the date of the last signature to this Agreement |
|
| January 5, 2023 |
EXHIBIT 99.1 Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes Exciting Data from University of Pittsburgh Researchers in Non Human Primates that Underpins Genprex?s Gene Therapy Program in Diabetes to be Showcased. AUSTIN, Texas ? (January 4, 2023) ? Genprex, Inc. (?Genprex? or the ?Company?) ( |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 12, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 28, 2022 |
EXHIBIT 10.1 CERTAIN IDENTIFIED INFORMATION MARKED WITH “[***]” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (“Agreement”) is made and entered into as of as of the date of the last signature to this Agreement (“Effective Date”), by and between t |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 22, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 21, 2022 |
EXHIBIT 99.1 |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 21, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 18, 2022 |
EXHIBIT 1.1 Genprex, Inc. Common Stock EQUITY DISTRIBUTION AGREEMENT Dated: November 18, 2022 TABLE OF CONTENTS SECTION 1. Description of Securities. SECTION 2. Placements. SECTION 3. Sale of Placement Securities by the Placement Agent SECTION 4. Suspension of Sales SECTION 5. Representations and Warranties. SECTION 6. Sale and Delivery to the Placement Agent; Settlement. SECTION 7. Covenants of t |
|
| November 18, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 18, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 18, 2022 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-239134 PROSPECTUS SUPPLEMENT (To Prospectus dated July 17, 2020) Up to $50,000,000 Common Stock On November 18, 2022, we entered into an Equity Distribution Agreement with JMP Securities LLC, or JMP Securities, related to shares of our common stock offered by this prospectus supplement. In accordance with the terms of the Equity Distribution Ag |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38244 GENPR |
|
| October 21, 2022 |
Exhibit 99.1 |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 21, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Comm |
|
| October 11, 2022 |
Exhibit 99.1 |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 11, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Comm |
|
| August 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 17, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 22, 2022 |
EXHIBIT 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. First Amendment to Exclusive License Agreement This First Amendment (the ?Amendment?) is dated as of August 17, 2022 and amends the Exclusive License Agreement (the ?Original Agreement?) dated as of February 10, |
|
| August 16, 2022 |
As filed with the Securities and Exchange Commission on August 15, 2022 As filed with the Securities and Exchange Commission on August 15, 2022 Registration No. |
|
| August 16, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Genprex, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Proposed Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.001 par value pe |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38244 GENPREX, I |
|
| August 12, 2022 |
EX-10.2 3 ex407420.htm EXHIBIT 10.2 Exhibit 10.2 THE PURCHASE RIGHTS EVIDENCED BY THIS WARRANT AGREEMENT AND THE SHARES OF CAPITAL STOCK ISSUABLE UPON EXERCISE OF SUCH PURCHASE RIGHTS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. SUCH SECURITIES CANNOT BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF WITHOUT REGISTRATION OF SUCH SECURITI |
|
| August 12, 2022 |
Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of May 17, 2022 by and between Genprex, Inc., a Delaware corporation (the ?Company?), and [?] (?Indemnitee?). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, the Board of Directors o |
|
| June 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 23, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38244 GENPREX, |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| May 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 5, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commissio |
|
| May 5, 2022 |
EXHIBIT 99.1 Genprex Issues Shareholder Letter and Provides 2022 Corporate Update Company achieves major milestones in clinical development programs in 2022 Patient treatment in Acclaim-2 clinical trial commences AUSTIN, Texas ? (May 5, 2022) ? Genprex, Inc. (?Genprex? or the ?Company?) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| April 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 27, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commis |
|
| April 27, 2022 |
Exhibit 99.1 |
|
| April 14, 2022 |
PRE 14A 1 gnpx20220301pre14a.htm FORM PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| March 31, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 30, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commis |
|
| March 31, 2022 |
EXHIBIT 99.1 Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA? Immunogene Therapy in Combination with Keytruda? to Treat Non-Small Cell Lung Cancer Company Has FDA Fast Track Designation for Combination of REQORSA and Keytruda AUSTIN, Texas ? (March 31, 2022) ? Genprex, Inc. (?Genprex? or the ?Company?) (NASDAQ: GNPX), a clinical-stage gene therapy |
|
| March 30, 2022 |
Description of Registrant's Securities. Exhibit 4.16 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Genprex, Inc. (the ?Company?) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), its common stock, par value $0.001 per share (the ?Common Stock?). Description of Common |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38244 Genprex, Inc. ( |
|
| March 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 2, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| March 2, 2022 |
EX-99.1 2 ex341745.htm EXHIBIT 99.1 EXHIBIT 99.1 Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Company has FDA Fast Track Designation for combination of REQORSA and Tagrisso Preclinical Data Presented at American Association of Clinical Research (AACR) 2021 Showed That REQ |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 4, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Comm |
|
| January 4, 2022 |
EXHIBIT 99.1 Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer Pipeline Expansion Enables Company to Target Entire Lung Cancer Market with REQORSA™ AUSTIN, Texas — (Jan. 4, 2022) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today |
|
| January 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 4, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| January 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 3, 2022 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| January 3, 2022 |
EXHIBIT 99.1 Genprex Receives U.S. FDA Fast Track Designation for REQORSA? Immunogene Therapy in Combination with Keytruda? for the Treatment of Non-Small Cell Lung Cancer Second FDA Fast Track Designation Further Validates the Potential of REQORSA AUSTIN, Texas ? (Jan. 3, 2022) ? Genprex, Inc. (?Genprex? or the ?Company?) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing |
|
| January 3, 2022 |
Exhibit 99.2 |
|
| November 17, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 17, 2021 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 17, 2021 |
Exhibit 99.1 |
|
| November 15, 2021 |
EXHIBIT 10.1 THE PURCHASE RIGHTS EVIDENCED BY THIS WARRANT AGREEMENT AND THE SHARES OF CAPITAL STOCK ISSUABLE UPON EXERCISE OF SUCH PURCHASE RIGHTS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. SUCH SECURITIES CANNOT BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF WITHOUT REGISTRATION OF SUCH SECURITIES UNDER ALL APPLICABLE FEDERAL AND |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38244 GENPR |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 15, 2021 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Comm |
|
| September 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 23, 2021 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Co |
|
| September 28, 2021 |
Exhibit 99.1 Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer Seasoned innovative drug development executives bolster leadership with relevant domain expertise as Company advances key Acclaim-1 and Acclaim-2 clincial trials of REQORSA systemic gene therapy in |
|
| September 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 28, 2021 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Co |
|
| September 28, 2021 |
Exhibit 10.1 September 9, 2021 Dear Dr. Berger: We are pleased to extend an offer of employment with Genprex, Inc. (the ?Company?) for the position of Chief Medical Officer. Your start date (the ?Start Date?) will be September 27, 2021, or such other date as the parties shall agree. You will report to the Chief Executive Officer and have such duties and responsibilities as shall be designated to y |
|
| September 28, 2021 |
Exhibit 10.4 GENPREX, INC. EMPLOYEE STOCK OPTION GRANT NOTICE AND OPTION AGREEMENT As a key leader in our business, you are in a position to have significant influence on the performance and success of Genprex, Inc. (the ?Company?). I am pleased to inform you that, in recognition of the role you play in our collective success, you have been granted an option to purchase shares of the Company?s Com |
|
| September 28, 2021 |
Exhibit 10.2 GENPREX, INC. EMPLOYEE STOCK OPTION GRANT NOTICE AND OPTION AGREEMENT As a key leader in our business, you are in a position to have significant influence on the performance and success of Genprex, Inc. (the ?Company?). I am pleased to inform you that, in recognition of the role you play in our collective success, you have been granted an option to purchase shares of the Company?s Com |
|
| September 28, 2021 |
Exhibit 10.3 September 3, 2021 Dear Dr. Kumar: We are pleased to extend an offer of employment with Genprex, Inc. (the ?Company?) for the position of Chief Manufacturing & Technology Officer. Your start date (the ?Start Date?) will be September 27, 2021, or such other date as the parties shall agree. You will report to the Chief Executive Officer and have such duties and responsibilities as shall |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38244 GENPREX, I |
|
| July 12, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 12, 2021 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90 - 0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| July 12, 2021 |
Exhibit 99.1 |
|
| June 28, 2021 |
Exhibit 99.1 Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA? Immunogene Therapy in Combination with Tagrisso? to Treat Non-Small Cell Lung Cancer Following FDA Review AUSTIN, Texas ? (June 23, 2021) ? Genprex, Inc. (?Genprex? or the ?Company?) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with ca |
|
| June 28, 2021 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 23, 2021 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90-0772347 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 17, 2021 |
Exhibit 4.1 THE PURCHASE RIGHTS EVIDENCED BY THIS WARRANT AGREEMENT AND THE SHARES OF CAPITAL STOCK ISSUABLE UPON EXERCISE OF SUCH PURCHASE RIGHTS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. SUCH SECURITIES CANNOT BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF WITHOUT REGISTRATION OF SUCH SECURITIES UNDER ALL APPLICABLE FEDERAL AND S |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38244 GENPREX, |
|
| May 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 13, 2021 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90 - 0772347 (State or other jurisdiction of incorporation or organization) (Commis |
|
| May 13, 2021 |
Exhibit 99.1 |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| March 26, 2021 |
EXHIBIT 4.13 THE PURCHASE RIGHTS EVIDENCED BY THIS WARRANT AGREEMENT AND THE SHARES OF CAPITAL STOCK ISSUABLE UPON EXERCISE OF SUCH PURCHASE RIGHTS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. SUCH SECURITIES CANNOT BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF WITHOUT REGISTRATION OF SUCH SECURITIES UNDER ALL APPLICABLE FEDERAL AND |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38244 Genprex, Inc. ( |
|
| March 26, 2021 |
EXHIBIT 4.12 THE PURCHASE RIGHTS EVIDENCED BY THIS WARRANT AGREEMENT AND THE SHARES OF CAPITAL STOCK ISSUABLE UPON EXERCISE OF SUCH PURCHASE RIGHTS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. SUCH SECURITIES CANNOT BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF WITHOUT REGISTRATION OF SUCH SECURITIES UNDER ALL APPLICABLE FEDERAL AND |
|
| March 26, 2021 |
EXHIBIT 10.29 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Amendment No. 1 to Patent and Technology License Agreement This Amendment No. 1 to Patent and Technology License Agreement (?Amendment No. 1?) is effective as of the date of the last authorized signature affixed |
|
| March 26, 2021 |
Warrant Agreement, dated August 10, 2020, issued to Capital City Technical Consulting, Inc. EX-4.11 2 ex236861.htm EXHIBIT 4.11 EXHIBIT 4.11 THE PURCHASE RIGHTS EVIDENCED BY THIS WARRANT AGREEMENT AND THE SHARES OF CAPITAL STOCK ISSUABLE UPON EXERCISE OF SUCH PURCHASE RIGHTS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. SUCH SECURITIES CANNOT BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF WITHOUT REGISTRATION OF SUCH SECURITI |
|
| March 26, 2021 |
Description of Registrant's Securities. EXHIBIT 4.14 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, Genprex, Inc. (the ?Company?) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), its common stock, par value $0.001 per share (the ?Common Stock?). Description of Common |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 19, 2021 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90 - 0772347 (State or other jurisdiction of incorporation or organization) (Comm |
|
| March 25, 2021 |
EXHIBIT 10.1 FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This First Amendment (the ?Amendment?) to the Employment Agreement is dated as of March 24, 2021 and effective as of March 19, 2021 (the ?Amendment Effective Date?) and is entered into by and between Genprex, Inc., a Delaware corporation (the ?Company?) and Catherine Vaczy (the ?Employee?). All capitalized terms used herein but not oth |
|
| March 25, 2021 |
EXHIBIT 10.2 FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This First Amendment (the ?Amendment?) to the Employment Agreement is dated as of March 24, 2021 and effective as of March 19, 2021 and is entered into by and between Genprex, Inc., a Delaware corporation (the ?Company?) and Michael Redman (the ?Employee?). All capitalized terms used herein but not otherwise defined shall have the mean |
|
| March 9, 2021 |
Exhibit 99.1 |
|
| March 9, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 3, 2021 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90 - 0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 2, 2021 |
Exhibit 99.1 |
|
| March 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 2, 2021 Date of report (Date of earliest event reported) GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 001-38244 90 - 0772347 (State or other jurisdiction of incorporation or organization) (Commi |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Genprex, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 372446104 (CUSIP Number) February 12, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 19, 2021 |
Joint Acquisition Statement Pursuant to Section 240.13d-1(k) Altium Capital Management, LP SC 13GA EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240. |
|
| February 16, 2021 |
Joint Acquisition Statement Pursuant to Section 240.13d-1(k) EX-1 2 ex-1.htm JOINT ACQUISITION STATEMENT Altium Capital Management, LP SC 13GA EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersign |
